Breaking News
Start for Free 0
📊 Q3 Earnings are here! Plan ahead with key data on upcoming stock reports - all in 1 place See list
Close

Sanofi SA (SASY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
101.16 +0.84    +0.84%
09/10 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  France
ISIN:  FR0000120578 
  • Volume: 1,088,304
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 100.08 - 101.16
Sanofi 101.16 +0.84 +0.84%

EPA:SASY Financials

 
Gain a comprehensive overview of Sanofi financials. Assess key figures from the balance sheet and income statement. Explore essential metrics such as total assets, total liabilities, equity, revenue, and net income to understand the company’s overall financial performance.

Sanofi reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was EUR 11,964 million compared to EUR 12,482 million a year ago. Net income was EUR 2,525 million compared to EUR 2,076 million a year ago. Basic earnings per share from continuing operations was EUR 2.01 compared to EUR 1.66 a year ago.For the nine months, sales was EUR 32,151 million compared to EUR 32,272 million a year ago. Net income was EUR 5,955 million compared to EUR 5,260 million a year ago. Basic earnings per share from continuing operations was EUR 4.76 compared to EUR 4.2 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

SASY Income Statement

Gross margin TTM 68.77%
Operating margin TTM 18.04%
Net Profit margin TTM 8.95%
Return on Investment TTM -
 Total Revenue  Net Income
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Revenue 12698 10588 10863 11456
Gross Profit 8857 7325 7784 7725
Operating Income 3477 1546 2821 1661
Net Income 2525 1435 1995 3111

SASY Balance Sheet

Quick Ratio MRQ 0.51
Current Ratio MRQ 1
LT Debt to Equity MRQ 17.2%
Total Debt to Equity MRQ 32.67%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Assets 125353 126722
Total Liabilities 52406 51570
Total Equity 72947 72947 75152 75152

SASY Cash Flow Statement

Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow  -
 Cash  Net Change in Cash
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change in Cash
* In Millions of EUR (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SASY Comments

Write your thoughts about Sanofi SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email